Q3 2018 13F Holders as of 30 Sep 2018
-
Type / Class
-
Equity / Common Stock, $0.0001 Par Value Per Share
-
Shares outstanding
-
107,800,271
-
Number of holders
-
131
-
Total 13F shares, excl. options
-
38,097,172
-
Shares change
-
-1,091,393
-
Total reported value, excl. options
-
$826,730,269
-
Value change
-
-$21,276,548
-
Put/Call ratio
-
51%
-
Number of buys
-
48
-
Number of sells
-
-56
-
Price
-
$21.70
Significant Holders of Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share (ITCI) as of Q3 2018
156 filings reported holding ITCI - Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share as of Q3 2018.
Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share (ITCI) has 131 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 38,097,172 shares
of 107,800,271 outstanding shares and own 35% of the company stock.
Largest 10 shareholders include FMR LLC (8,206,241 shares), Vanguard Group Inc (3,943,792 shares), BlackRock Inc. (3,928,310 shares), BB BIOTECH AG (2,200,000 shares), WASATCH ADVISORS INC (1,928,018 shares), DIMENSIONAL FUND ADVISORS LP (1,419,888 shares), SCHRODER INVESTMENT MANAGEMENT GROUP (1,200,906 shares), STATE STREET CORP (1,004,622 shares), CITADEL ADVISORS LLC (778,193 shares), and SAMLYN CAPITAL, LLC (771,220 shares).
This table shows the top 131 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.